BioCentury
ARTICLE | Clinical News

Eylea aflibercept ophthalmic solution regulatory update

November 11, 2013 8:00 AM UTC

Regeneron and Bayer submitted regulatory applications in the U.S. and EU seeking to expand the label of Eylea aflibercept to include diabetic macular edema (DME). Bayer, which has ex-U.S. rights to Ey...